| 臺大學術典藏 |
2022-08-19T00:20:52Z |
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
|
Kim W.S.; Kwong Y.-L.; Suh C.; Lim S.T.; Cheng A.-L.; Chng W.-J.; Lee J.; Intragumtornchai T.; Kim S.J.; CHIUN HSU; Song Y.-Q.; Tay K.; Hong X.-N.; Cao J.; Kim J.S.; Eom H.S.; Lee J.H.; Zhu J.; Chang K.-M.; Reksodiputro A.H.; Tan D.; Goh Y.T. |
| 臺大學術典藏 |
2022-08-19T00:20:53Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Liu S.-H.; Cheng A.-L.; Lin C.-Y.; Chang C.-Y.; Lin K.-L.; CHIUN HSU; Ou D.-L.; Shen Y.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:53Z |
Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
|
Liou J.-Y.; CHIUN HSU; Cheng A.-L.; Lin L.-I.; Lee B.-S.; Chang Y.-C.; Ou D.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:53Z |
14-3-3�` Overexpression Contributes to Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma
|
Wu Y.-M.; Liou J.-Y.; Wang J.; CHIUN HSU; Chen S.-C.; Liang S.-M.; Ko B.-S.; Jan Y.-J.; Liu T.-A. |
| 臺大學術典藏 |
2022-08-19T00:20:54Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Cheng A.-L.; Lu Y.-S.; Chen W.-W.; Chang D.-Y.; Huang S.-M.; Lin C.-H.; CHIUN HSU; Lin M.-H.; Huang C.-S. |
| 臺大學術典藏 |
2022-08-19T00:20:54Z |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
Yeh K.H.; Hu F.C.; Chang S.Y.; Kao H.F.; Chen Y.C.; Chien S.F.; Chen I.C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Shau W.-Y.; Chen T.-J.; Yang S.-H.; Huang S.-M.; CHIUN HSU; Lu Y.-S.; Cheng A.-L.; Lin C.-H.; Kuo Y.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shen Y.-C.; Hsu C.-H.; Cheng A.-L.; CHIUN HSU; Lin Z.-Z.; Lu L.-C.; Shao Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
Comparative microRNA detection from precursor-microRNA-transfected hepatocellular carcinoma cells by capillary electrophoresis with dual-color laser-induced fluorescence
|
Yang T.-H.; Ou D.-L.; CHIUN HSU; Huang S.-H.; Chang P.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:55Z |
erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)
|
CHIUN HSU; Shen Y.-C.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:56Z |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression
|
Yeh K.-H.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Shen Y.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.; Chang D.-Y.; Hu F.-C.; Shao Y.-Y.; CHIUN HSU; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Cheng A.-L.; Meng R.; Chao Y.; Hsieh T.-Y.; Huang W.-T.; Hwang W.-S.; Yu C.-W.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regression
|
Shen Y.-C.; CHIUN HSU; Cheng C.-C.; Hu F.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; CHIUN HSU; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Antiangiogenic strategies for the treatment of hepatocellular carcinoma
|
CHIUN HSU; Shen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:59Z |
Increased expression of 14-3-3�] promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma
|
Shen T.-L.; Lee Y.-M.; Chen P.-F.; Wang J.; Shyue S.-K.; Liou J.-Y.; CHIUN HSU; Liang S.-M.; Hung Y.-L.; Chen S.-C.; Jan Y.-J.; Ko B.-S.; Liu T.-A. |
| 臺大學術典藏 |
2022-08-19T00:20:59Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Lu Y.S.; Cheng A.L.; Kuo W.H.; Chen I.C.; Lin C.H.; Huang C.S.; Lien H.C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:21:00Z |
Overexpression of 14-3-3�` predicts tumour metastasis and poor survival in hepatocellular carcinoma
|
Liou J.-Y.; Ko B.-S.; Chang T.-C.; CHIUN HSU; Chen Y.-C.; Shen T.-L.; Chen S.-C.; Wang J.; Wu K.K.; Jan Y.-J. |
| 臺大學術典藏 |
2022-08-19T00:21:00Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Hsu C.-H.; Hu F.-C.; CHIUN HSU; Yu C.-W.; Shen Y.-C.; Hsu C.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:01Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Shao Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:02Z |
Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma
|
Whang-Peng J.; Cheng A.-L.; CHIUN HSU; Chen C.-M. |
| 臺大學術典藏 |
2022-08-19T00:21:02Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H.; Chang K.-J.; Kuo W.-H.; CHIUN HSU; Lee W.-C.; Liau J.-Y.; Huang C.-S.; Lu Y.-S.; Shao Y.-Y.; Kuo K.-T.; Hu F.-C. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Cheng A.-L.; Ding Y.-H.; CHIUN HSU; Shao Y.-Y.; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H. |
